Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
Allogene Therapeutics, Inc. (ALLO)
Sector: Healthcare; Industry: Biotechnology

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2022-01-12 Belldegrun Arie Director Buy 155,039 $12.60 $1,953,491 No
2020-06-04 Belldegrun Arie Director Buy 146,382 $47.00 $6,879,954 No
2018-10-15 Belldegrun Arie Director Buy 194,445 $18.00 $3,500,010 No
2018-10-15 Belldegrun Arie 10%-Owner, Director Buy 35,000 $18.00 $630,000 Yes

Insider Smart

ROYAL CARIBBEAN CRUISES (RCL) - Thompson Donald, Director of RCL feels safe and made a move. The only insiders bought RCL post crash.

Insider Smart

Enphase Energy, Inc (ENPH) - ENPH was $10+ in 15Q1 then dropped to $2 and eventually went under $1. From 15Q4 to 17Q4 it built a 2-year-long base then BOOM! Stock went as high as $70 and likely will make a new high. Catch one or two moves like this you can retire early. One hint before the big move was that CEO and CFO were constantly accumulating, this kind of information is priceless.